Company news

Pulmatrix, Inc. news in 2023

Pulmatrix, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 8, 2023

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

September 18, 2023

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

August 22, 2023

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 9, 2023

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

July 10, 2023

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

June 14, 2023

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 23, 2023

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023

Pulmatrix Supports World Asthma Day 2023

May 1, 2023

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

March 29, 2023

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

February 5, 2023

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

January 24, 2023

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

January 22, 2023

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

January 3, 2023

Decks in 2023